ResearcherUniversidad Complutense de MadridNo recent work listed

Álvaro Gregorio Morales Taboada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1479-6607; OpenAlex author ID A5006289454. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper

Papers 2

Neoadjuvant therapy impact in early pancreatic cancer: "bioborderline" vs. "non-bioborderline". Co-author DOI 10.14701/ahbps.22-023 ↗
Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades. Co-author DOI 10.14701/ahbps.2021.25.2.179 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Andrés Jesús Muñoz Martín · 2 shared papers, 2021–2022 · strength 0.33
- Paper Neoadjuvant therapy impact in early pancreatic cancer: "bioborderline" vs. "non-bioborderline". DOI 10.14701/ahbps.22-023 ↗
- Paper Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades. DOI 10.14701/ahbps.2021.25.2.179 ↗
José Manuel Asencio · 2 shared papers, 2021–2022 · strength 0.33
- Paper Neoadjuvant therapy impact in early pancreatic cancer: "bioborderline" vs. "non-bioborderline". DOI 10.14701/ahbps.22-023 ↗
- Paper Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades. DOI 10.14701/ahbps.2021.25.2.179 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.